Marcus from Singapore

Registered at the short selling broker Capital, 4 minutes ago.

» Try Capital you too
67.7% of retail investor accounts lose money when trading CFDs with Capital.
Don't show again

Johnson & Johnson (JNJ) shares information

Johnson & Johnson

24h Change

-0.72 %


Live rate: Market closed

Stock data per Friday 22 Sep, 2023

-1.16 (-0.72%)
US Market is closed

Live Stock price in graph for Johnson & Johnson (JNJ)

  • Latest Volume

    4,977,354 (9.95 %)

  • Volume prev. day


  • Avg. daily volume


  • Market cap


  • P/E ratio


  • Today high

    161.4 USD

  • Today low

    160.25 USD

  • 52 week high

    177.11 USD

  • 52 week low

    147.91 USD

  • YTD Change


Quick links


Latest news about Johnson & Johnson

Below you can find the most recent news posts about Johnson & Johnson, primarily from US and UK based news sources.

Johnson & Johnson: The Bull Case Can No Longer Be Ignored

Saturday, 23 September 2023, 14:30:00
JNJ”s best-in-class
— Seeking Alpha

Cidara Therapeutics: Reduced Risk Due To Janssen”s Decision And Progress In The Oncology Pipeline

Saturday, 23 September 2023, 01:48:58
Janssen”s collaboration with Cidara Therapeutics validates the potential of their platform. Find out why CDTX stock is a strong buy, despite its limited cash runway.
— Seeking Alpha

Protagonist Therapeutics: There Are Reasons Behind Johnson & Johnson”s Optimism

Friday, 22 September 2023, 21:35:32
We look at the pros and cons of J&J”s oral IL-23 drug, JNJ-2113, compared to Protagonist Therapeutics, Inc.”s oral treatment. Click for more on PTGX.
— Seeking Alpha

South Africa launches ‘unprecedented’ investigation of Johnson & Johnson over TB drug prices

Friday, 22 September 2023, 07:30:09
Competition watchdog probes claims of profiteering by US drugmaker in country where tuberculosis is biggest killer South Africa’s Competition Commission will investigate the American drugmaker Johnson & Johnson for the high price it has been charging for the tuberculosis medicine bedaquiline, as well as for extending its 20-year patent until 2027 to block cheaper generics from entering the country. The commission’s investigation was made public last week by the health department and the Health Justice Initiative (HJI) legal organisation at a media briefing of Médecins Sans Frontières (MSF). The commission investigates matters when it has reasonable suspicion of exploitative or unethical behaviour. This story was produced by the Bhekisisa Centre for Health Journalism . Readers can sign up here for the centre’s newsletter Continue reading…
— The Guardian

A Comprehensive Timeline Of COVID-19 Vaccines And Myocarditis

Friday, 22 September 2023, 04:20:00
A Comprehensive Timeline Of COVID-19 Vaccines And Myocarditis Authored by Zachary Stieber via The Epoch Times (emphasis ours), 2020 Sept. 22, 2020: U.S. Centers for Disease Control and Prevention (CDC) identifies myocarditis as an adverse event of special interest, or a potential side effect. Oct. 30, 2020: U.S. Food and Drug Administration (FDA) identifies myocarditis as an adverse event of special interest. December 2020: One case of pericarditis reported to the U.S. Vaccine Adverse Event Reporting System (VAERS), which is co-managed by the CDC and FDA. Dec. 11, 2020: FDA authorizes the Pfizer-BioNTech vaccine for Americans 16 and older. Dec. 13, 2020: CDC launches V-safe, a new vaccine safety monitoring system, without including myocarditis as an option in the adverse events list. Dec. 18, 2020: FDA authorizes the U.S. government-backed Moderna vaccine for Americans 18 and older. 2021 2021: Myocarditis cases spike in the U.S. military. January 2021: 28 cases of myocarditis, pericarditis, or myopericarditis reported to VAERS.
— Zero Hedge

Trading broker recommendation

We recommend that you check out as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €250 by bank
Description: offer a large number of stocks for trading. Register an account today and check if they have JNJ available or trade one of the many other CFD stocks they have.
Risk warning: 67.7% of retail investor accounts lose money when trading CFDs with Capital.